Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Fulcrum Therapeutics, Inc. | Chief Legal Officer | Stock Option (right to buy) | 150K | Jan 26, 2024 | Direct | ||
AVENUE THERAPEUTICS, INC. | Director | Employee stock option (right to buy) | 30K | Sep 23, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ATXI | AVENUE THERAPEUTICS, INC. | Sep 23, 2024 | 1 | $0 | 4 | Sep 25, 2024 | Director |
FULC | Fulcrum Therapeutics, Inc. | Jan 26, 2024 | 1 | $0 | 4 | Jan 30, 2024 | Chief Legal Officer |
ATXI | AVENUE THERAPEUTICS, INC. | Jun 30, 2023 | 1 | $0 | 4 | Jul 5, 2023 | Director |
FULC | Fulcrum Therapeutics, Inc. | Apr 26, 2023 | 1 | $0 | 4 | Apr 28, 2023 | Chief Legal Officer |
FULC | Fulcrum Therapeutics, Inc. | Feb 9, 2023 | 1 | $0 | 4 | Feb 13, 2023 | Chief Legal Officer |
FULC | Fulcrum Therapeutics, Inc. | Aug 9, 2022 | 1 | $0 | 4 | Aug 11, 2022 | Chief Legal Officer |
FULC | Fulcrum Therapeutics, Inc. | Jan 19, 2022 | 1 | $0 | 4 | Jan 21, 2022 | SVP, General Counsel |
FULC | Fulcrum Therapeutics, Inc. | Dec 31, 2021 | 1 | $0 | 5 | Jan 7, 2022 | SVP, General Counsel |
ATXI | AVENUE THERAPEUTICS, INC. | Dec 17, 2021 | 1 | $0 | 4 | Dec 21, 2021 | Director |
FULC | Fulcrum Therapeutics, Inc. | Jun 28, 2021 | 1 | $9.8K | 4 | Jun 29, 2021 | SVP, General Counsel |
ATXI | AVENUE THERAPEUTICS, INC. | Apr 1, 2021 | 0 | $0 | 3 | Dec 21, 2021 | Director |